{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-074915","form_type":"8-K","ticker":"VSTM","cik":"0001526119","company_name":"Verastem, Inc.","filed_at":"2026-06-17T12:52:16+00:00","discovered_at":"2026-06-17T12:55:00.334708+00:00","generated_at":"2026-06-17T12:55:10.105684+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Verastem reports 86% 6-month OS rate in RAMP 205 pancreatic cancer trial; starts VS-7375 Phase 2","bullets":["6-month OS rate 86%, ORR 52%, and 83% tumor shrinkage in RAMP 205 RP2D cohort (n=29).","9 patients remain on treatment; median follow-up 9.8 months; no new safety signals.","First patient dosed in TARGET-D 201 Phase 2 registration trial of VS-7375 (KRAS G12D) in second-line mPDAC.","PanCAN provided $3.8M Therapeutic Accelerator Award in 2022 for RAMP 205 research."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-074915","json":"https://secwatch.observer/filing/0001104659-26-074915.json","markdown":"https://secwatch.observer/filing/0001104659-26-074915.md","text":"https://secwatch.observer/filing/0001104659-26-074915.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1526119/000110465926074915/0001104659-26-074915-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1526119/000110465926074915/tm2618108d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T12:55:10.105684+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}